Q-omics provides the consensus-scored NUDT17 profile across patient tissues and cancer cell-line models. NUDT17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NUDT17 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, NUDT17 RNA expression shows 19,182 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, LIHC, and ACC as cancer lineages where NUDT17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT17 survival associations across molecular data types. NUDT17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT17 RNA expression–survival associations across cancer types. High NUDT17 expression shows unfavorable associations in COAD, KIRC, LIHC, ACC and MESO, but favorable associations in BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NUDT17 RNA expression.
This table summarizes NUDT17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT17 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, THCA, KIRC and CHOL. The LIHC box plot shows higher NUDT17 RNA expression in tumor versus normal tissue (log2 FC = +1.245, t-test p < 0.001).
This table shows molecular features associated with NUDT17 in patient tissues and cancer cell lines. In patient samples, NUDT17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
